in developing drug candidates for evaluation and progression in the clinic. Progenra’s expertise in developing small molecule E3 ligase modulators is being harnessed to create novel classes of PROTAC molecules to expand the scope of this promising new avenue of proteostasis-based therapeutics. Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system and cellular protein regulation, acquired over several years, to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas.